From Plant Extract to Anticancer Candidate: What Makes a Natural Product Study Convincing?

Back to previous results

Cancer BiologyOctober 31, 20265 min read

How researchers move from an interesting extract to reproducible, biologically meaningful evidence.

AuthorKhaled Mahmud SujonView portfolio / profile ↗

Research Associate, MBPSL.

Plant-derived compounds are valuable starting points for drug discovery. Learn how researchers move from an interesting extract to reproducible, biologically meaningful evidence.

A plant extract that reduces cancer-cell viability in a laboratory assay may be interesting. It is not, by itself, evidence that the extract is a safe or effective cancer treatment. The strength of a natural-product study depends on the quality of the material, the design of the experiments and the depth of the biological validation.

Plants produce chemically diverse molecules as part of their interactions with the environment. Some of these molecules have become important starting points for medicines, including compounds and derivatives used in oncology. For researchers, the opportunity is exciting: natural products can provide chemical structures and biological activities that may be difficult to anticipate through conventional screening alone. The challenge is turning an early observation into a reliable, testable research finding.

1. Start by defining the material

“Plant extract” is not a sufficiently precise description of an experimental material. A robust study should document the identity of the plant, the plant part used, its origin, authentication or voucher information, extraction solvent, extraction procedure, yield, storage conditions and batch. Different growing conditions, harvest periods and extraction methods can produce substantially different chemical profiles.

Where possible, researchers should chemically characterise the extract or fraction using suitable analytical methods, such as HPLC or LC–MS. A chemical fingerprint helps establish whether different batches are comparable and gives later experiments a more reproducible starting point. If a purified compound is being tested, its identity and purity should also be established.

2. Treat cell-viability screening as a first filter

Cell-based assays such as MTT, resazurin or sulforhodamine B can help estimate how a test material affects cell growth or viability. Concentration–response experiments are more informative than testing a single dose. Researchers should also report exposure time, cell seeding density, vehicle concentration, biological replicates and the controls used.

There is an important limitation: different assays measure different biological or chemical properties. A coloured or redox-active plant extract may interfere with an assay signal, and a change in metabolic activity does not necessarily mean that cells have died. A fall in a single viability readout cannot distinguish reduced proliferation from apoptosis, necrosis, temporary metabolic suppression or technical interference.

Good practice: confirm an initial screening result with at least one independent, biologically appropriate readout. Include cell-free or extract-only controls where assay interference is plausible, as well as suitable positive, negative and vehicle controls.

3. Ask whether the effect is selective

An anticancer candidate should ideally affect malignant cells more strongly than relevant non-malignant cells at comparable exposures. Testing only one cancer cell line cannot establish broad anticancer activity, and testing no normal-cell comparator makes it difficult to interpret selectivity. Researchers should use authenticated cell lines, document their provenance and passage history, and routinely monitor cultures for contamination, including mycoplasma.

Reported IC50 values are useful for summarising an assay-specific concentration response, but they are not universal measures of therapeutic value. They depend on the cell model, assay chemistry, exposure time and experimental conditions. A potent result in a dish may still be irrelevant if the required concentration cannot be achieved safely in a living system.

4. Move from cell response to mechanism

Once a reproducible effect is established, researchers can investigate the biological processes involved. In cancer biology, questions may include whether treatment alters cell-cycle progression, mitochondrial function, oxidative balance or regulated cell-death pathways. Proteins and genes such as BAX, BCL-2, p53 and caspases can be useful parts of a mechanistic investigation, depending on the model and the initial findings.

However, a change in gene expression does not prove that a gene caused the observed phenotype. Stronger mechanistic evidence combines complementary approaches: time-course experiments, protein-level measurements, direct cell-death assays, pathway-specific perturbation and rescue experiments. The selected methods should test a clearly stated hypothesis rather than simply generate a long list of altered markers.

5. Consider the translational gap

Before a candidate can be considered for therapeutic development, it needs further evaluation beyond conventional cell culture. This may include chemical standardisation, stability, solubility, absorption and metabolism, exposure at the target tissue, toxicity, and appropriate in vivo studies. More complex models—such as three-dimensional cultures, organoids or patient-derived systems—can help address questions that simple monolayer cultures cannot answer.

These steps are not formalities. They determine whether an apparent biological effect is reproducible, selective and achievable under conditions relevant to a living organism.

How this connects with MBPSL research

MBPSL’s research portfolio includes the investigation of bioactive compounds and their effects in cancer models. The laboratory’s research page lists a 2021 study comparing the biological potential and Ehrlich ascites carcinoma (EAC) cell-growth-inhibition activity of fruit pulp and seeds of Phyllanthus acidus. That work provides a useful local example of exploratory natural-product research; it should be interpreted as preclinical evidence, not as proof of a human treatment.

The central message: a credible natural-product study does more than report that an extract “kills cancer cells”. It identifies and standardises the material, measures the response carefully, checks selectivity, investigates mechanism and is transparent about what remains unknown.

Further reading

  1. MBPSL. Research facilities and publications — includes the laboratory’s listed Phyllanthus acidus study. View MBPSL research.
  2. Talib, W. H. et al. (2020). Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation. Read the review.
  3. Gavanji, S. et al. (2023). Cytotoxic Activity of Herbal Medicines as Assessed in Vitro: A Review. PubMed record.
  4. ATCC. Cell Line Authentication Test Recommendations. Read the technical guidance.

This article is an educational overview. It does not evaluate any specific extract as a medicine and does not provide treatment advice.

5reads